Overview

Study of Alvocidib in Patients With Relapsed/Refractory AML Following Treatment With Venetoclax Combination Therapy

Status:
Active, not recruiting

Trial end date:
2021-11-01

Target enrollment:

Participant gender:

Summary

This study will evaluate the safety and efficacy of alvocidib in patients with AML who have either relapsed from or are refractory to venetoclax in combination with azacytidine or decitabine.

Phase:

Phase 2

Details

Lead Sponsor:

Sumitomo Dainippon Pharma Oncology, Inc
Tolero Pharmaceuticals, Inc.

Treatments:

Alvocidib
Cytarabine
Venetoclax